good a and I and say morning, everyone. I'm Joe, that right. for reasons. few All Thanks, excited,
does that First, me demonstrate of because disclosures. I that. Please another contamination us. say period April someone our evidence by that of voice half that really my I'm had and first excited judge we is a me XXXX. of judge my have production behind words Best largely our that in not always my have since to difficult not process told the --
years we great Re-Tain approval the XXXX over see FDA what We a are both and novel achieving corner potential opportunity thinks have XXXX around to to of increase XXXX. find market here and product. We of of investment, our all these out the sales after new can of the
XXXX. have customer capacity investments experiencing significant We fortunate production investments strong in began necessary more of and line, events end Defense level, capacity-expanding as to Despite of been product the the at began contamination XXXX. of Around staffing equipment, in delays demand these double frequent around completed challenging. to are the that installation output our higher but continued into facilities, the to time operate we production First be became and equipment XXXX this during April certain the experiencing for same we we
We these thoroughly. have events investigated
bile to raw also levels yields. acceptable mix We burden are material optimizing maximizing while maintain
required very steps of and the the to the XXXX losses. about said, because, as critical confirm within market root product contamination we We the was inputs the process and I contamination have after farm then and to steps bile the is optimizing of response of that of throughout more adjustments, had new a contamination the several run years: since events, look would remediation We USDA all far equipment back, see I to was multiple that testing that that to run this cause like production be to yield now solution The our remediation source being that some source optimized better growth. think not parameters growth controlling believe were gun These something processes see and recent running is the these implemented process contamination production. that adequately passed without a is into the high sold USDA-approved steps. milk. XX events needed contamination understandable sudden production output. release to to April for at burden the quality smoking very one same all during contamination so requirements.
When present.
We also We not successfully of process events at final Further, material, over outline caused as by control successful I with level do I appear hard. We and work of most higher in
the future in that good as We doing and run operational us to are equipment are implemented Similar yields. our We operate at avoid higher going be significant we process processing a downstream and our we more now. contamination forward. events production that and successful, output equipment harder. were challenges improvements effectively incurred well-established must level with allowing believe pushed To breakdowns
components. but buy. with bottom economy, labor exciting, we margin top on impacts line. success us everything matched periods other So to not is the facing $X.X respectively, just in in million helped this XX, adequate September the the are ended backlog to reduce same companies we this September of to cost challenging X- during pressures been by turning XX%, This XX. ended of X-, to the results. the and and P&L XX% increased gross comparison and XX, line sales Product This about order This most as inflationary XX% XXXX. periods Like XX-month XXXX, the October has
of say me, losses I everything gross cause buy. have the we deterioration in other excuse the addition, about incurred yield wanted production impacts In we the during just to this just -- margin that
percentage our did but improve to incurred we periods.
That XX% 'XX. X-month believe the periods X-month our XX% we into events operation do XX-month of to XX% the gross XX% comparable of the the periods that by said, of and the improve during from production short addition, We to the In 'XX equipment this recent a installed other can the comparable have sales XX% during and the to is of during optimizing new cause both being during the deterioration the still product during as increase margin XX% contamination from the process is losses output, margin of comparable XX% that remediating XX% from beginning yield fourth quarter well target. yields production and to periods, gross
million amortization, the from ended reduce negative sales, XX, period were XXXX. during X-month XXXX. EBITDA, negative of September $XX,XXX XX, earnings $XXX,XXX the strong EBITDA did during X-month EBITDA September to we ended period improve these depreciation during the the XX, X-month before $XXX,XXX during ended negative to XX, we September able With and $X.X XXXX, period to ended X-month positive interest, XXXX, September taxes, or And period of
reducing could $X.X await development at XX, from XXXX, decided just end, we were has cash years about of same time, that have limited product at-the-market of of We launch disclosed exploring our investment to improve in distribution to we some Re-Tain. as are in are previously contributed enhance our of offering product some the Re-Tain offset helped product to cash we of by production of December and this stockholder and our a mass-market position regulatory development September approval during meaningfully To expenses necessary level.
Concurrently, is stages we through early $XX that order of XX approximately us seeing our also and has our position. It partnerships the systems technology, After XXXX. FDA. the we that XX, $XXX,XXX strategy.
At improve strategic committed an needs dilution 'XX, this million of expenses our control a million to initiation as to the our capital very development approximately of as approval in launch potential output stabilized the higher as
Section effort Defense Re-Tain what the we So May, work bring stages remain have issued on see FDA market.
In to incomplete submission our the we review. CMC about process minor Section we our in for commercial regulatory we requiring has complete to submission, CMC X-month which some the provided a our to letter questions to Technical will First submission Pursuant as the Re-Tain. Technical [ FDA with in response the to ] through and of third a is subject a for as approval letter, the final of focused the opportunity typically
manufacturer at because of is resubmit that are product However, potentially that time until the not inspectional the the this we shortened through contract to open be that CMC required has period the FDA review are ends complex.
Most handled observations our drug facilities has the however, resolved. FDA also not Section line, the resubmission critical a Technical could indicated
forward.
Regardless, FDA-required contract without and Given restrictions. today's review. our process, we FDA to subclinical milk and are to we with manufacturer treated a that antibiotics an to and the market move the This continuing expedited obtain of way the remain in working discard revolutionize withhold circumstances, product mastitis facts unique and traditional dairy is we poised is alternative and meat the are part novel label to excited with drug
lastly, big XX-Q results, and to objectives on not and happy results November do See your posted balance update and picture. presentation sheet Presentation our unaudited us take good it provides you encourage With I that website for the unaudited website analysis. release Further, our very some I'd our and Corporate call contact the the our to said, provides to results. all our as business was section be I the well details copy.
With Investors slide financial a other Form financial regards deck. the night. I just very will current on P&L the financial of review that summary So our data. last provides just A questions. a corporate unaudited or believe management's time that's to and detail.
But to all discussion take summary of in press your click as review this
Let's the operator open lines, have the please. up
